Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Tuning Hsp104 specificity to selectively detoxify α-synuclein

View through CrossRef
Summary Hsp104 is an AAA+ protein disaggregase that solubilizes and reactivates proteins trapped in aggregated states. We have engineered potentiated Hsp104 variants to mitigate toxic misfolding of α-synuclein, TDP-43, and FUS implicated in fatal neurodegenerative disorders. Though potent disaggregases, these enhanced Hsp104 variants lack substrate specificity, and can have unfavorable off-target effects. Here, to lessen off-target effects, we engineer substrate-specific Hsp104 variants. By altering Hsp104 pore loops that engage substrate, we disambiguate Hsp104 variants that selectively suppress α-synuclein toxicity but not TDP-43 or FUS toxicity. Remarkably, α-synuclein-specific Hsp104 variants emerge that mitigate α-synuclein toxicity via distinct ATPase-dependent mechanisms, involving α-synuclein disaggregation or detoxification of α-synuclein conformers without disaggregation. Importantly, both types of α-synuclein-specific Hsp104 variant reduce dopaminergic neurodegeneration in a C. elegans model of Parkinson’s disease more effectively than non-specific variants. We suggest that increasing the substrate specificity of enhanced disaggregases could be applied broadly to tailor therapeutics for neurodegenerative disease.
Title: Tuning Hsp104 specificity to selectively detoxify α-synuclein
Description:
Summary Hsp104 is an AAA+ protein disaggregase that solubilizes and reactivates proteins trapped in aggregated states.
We have engineered potentiated Hsp104 variants to mitigate toxic misfolding of α-synuclein, TDP-43, and FUS implicated in fatal neurodegenerative disorders.
Though potent disaggregases, these enhanced Hsp104 variants lack substrate specificity, and can have unfavorable off-target effects.
Here, to lessen off-target effects, we engineer substrate-specific Hsp104 variants.
By altering Hsp104 pore loops that engage substrate, we disambiguate Hsp104 variants that selectively suppress α-synuclein toxicity but not TDP-43 or FUS toxicity.
Remarkably, α-synuclein-specific Hsp104 variants emerge that mitigate α-synuclein toxicity via distinct ATPase-dependent mechanisms, involving α-synuclein disaggregation or detoxification of α-synuclein conformers without disaggregation.
Importantly, both types of α-synuclein-specific Hsp104 variant reduce dopaminergic neurodegeneration in a C.
elegans model of Parkinson’s disease more effectively than non-specific variants.
We suggest that increasing the substrate specificity of enhanced disaggregases could be applied broadly to tailor therapeutics for neurodegenerative disease.

Related Results

Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins
Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins
Abstract Protein misfolding is implicated in numerous lethal neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and Parkinson disease (PD). T...
Engineering Hsp104 Variants to Counter Protein Misfolding
Engineering Hsp104 Variants to Counter Protein Misfolding
There are no therapies that reverse the proteotoxic misfolding events that underpin fatal neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and Parkinson's d...
Novel β-synuclein Rearrangements in tumor
Novel β-synuclein Rearrangements in tumor
Abstract Purpose The synuclein family includes a-, b-, g-synuclein and is predominantly expressed in neurons. a- and b-synuclein is mutated in Parkinson's disease and demen...
Therapeutic genetic variation revealed in diverse Hsp104 homologs
Therapeutic genetic variation revealed in diverse Hsp104 homologs
ABSTRACT The AAA+ protein disaggregase, Hsp104, increases fitness under stress by reversing stress-induced protein aggregation. We have engineere...
The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models
The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models
Animal models of Parkinson’s disease, in which the human α-synuclein transgene is overexpressed in the nigrostriatal pathway using viral vectors, are widely considered to be the mo...
Electric field tuning characteristic of multiple optical parametric oscillator based on MgO:QPLN
Electric field tuning characteristic of multiple optical parametric oscillator based on MgO:QPLN
The quasi-phase matching optical parametric oscillator tuning methods, i.e. grating period tuning, temperature tuning, pumping wavelength tuning, and angle tuning are more simple a...
CNTNAP4 partial deficiency exacerbates α -synuclein pathology through astrocyte–microglia interplay
CNTNAP4 partial deficiency exacerbates α -synuclein pathology through astrocyte–microglia interplay
Abstract BackgroundParkinson’s disease (PD) is a common progressive neurodegenerative movement disorder, which is characterized by dopaminergic (DA) neuron death and the ag...
Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization
Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization
AbstractAccumulation of α-synuclein aggregates in the substantia nigra pars compacta is central in the pathophysiology of Parkinson’s disease, leading to the degeneration of dopami...

Back to Top